Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ: GERN )

3.490 -0.170 (-4.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,318,735
Open 3.610
Bid (Size) 3.490 (6)
Ask (Size) 3.520 (17)
Prev. Close 3.660
Today's Range 3.455 - 3.685
52wk Range 1.690 - 5.340
Shares Outstanding 508,766,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire

Performance

YTD
+63.08%
+63.08%
1 Month
-14.25%
-14.25%
3 Month
-18.46%
-18.46%
6 Month
-23.97%
-23.97%
1 Year
+51.08%
+51.08%

More News

Read More
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
Analyst Scoreboard: 4 Ratings For Geron
Via Benzinga
Analyst Ratings For Geron
Via Benzinga
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron (GERN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
From Geron
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.